Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Sangamo Therapeutics (SGMO) over the last 9 years, with Q1 2025 value amounting to $15000.0.

  • Sangamo Therapeutics' Non-Current Deferred Tax Liability changed N/A to $15000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $15000.0, marking a year-over-year change of. This contributed to the annual value of $5.8 million for FY2023, which is 7951.44% down from last year.
  • As of Q1 2025, Sangamo Therapeutics' Non-Current Deferred Tax Liability stood at $15000.0.
  • Sangamo Therapeutics' Non-Current Deferred Tax Liability's 5-year high stood at $31.2 million during Q4 2021, with a 5-year trough of $15000.0 in Q1 2025.
  • For the 4-year period, Sangamo Therapeutics' Non-Current Deferred Tax Liability averaged around $10.0 million, with its median value being $6.5 million (2022).
  • In the last 5 years, Sangamo Therapeutics' Non-Current Deferred Tax Liability surged by 661.08% in 2021 and then tumbled by 7951.44% in 2023.
  • Sangamo Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $31.2 million in 2021, then dropped by 9.84% to $28.1 million in 2022, then plummeted by 79.51% to $5.8 million in 2023, then crashed by 99.74% to $15000.0 in 2025.
  • Its last three reported values are $15000.0 in Q1 2025, $5.8 million for Q4 2023, and $6.4 million during Q1 2023.